uncertainty of a cure with high-dose, intensive treatment regimens. While there has been increasing attention paid to QOL issues in BMT patients, [3][4][5][6][7][8][9] there have been few We developed a 12-item bone marrow transplant subscale (BMTS) for the general Functional Assessment of instruments designed specifically to measure quality of life in the transplant patient population. One other available Cancer Therapy (FACT) measure. The subscale combined with the FACT, (FACT-BMT) is a 47-item, valid instrument 10 was developed for post-treatment survivors of bone marrow transplantation, so its appropriateness for and reliable measure of five dimensions of quality of life in bone marrow transplant patients. The three-step patients during transplantation is unknown.
11,12
Initially, general measures of psychological health and assess content not represented in the general FACT items. A total of 182 patients completed the FACT-BMT functional status were used to assess patient response to cancer therapies and other areas such as cardiac care and at baseline, prior to BMT. An analysis measuring sensitivity to change was performed with 74 patients after renal transplantation. Cancer specific instruments were developed to measure the particular issues faced by cancer transplantation and 60 patients over the three timepoints of baseline, hospital discharge and 100 days. The patients. 13, 14 Further advancement of QOL measurement technology has produced site-specific scales that FACT-BMT and all subscales were correlated, sensitivity to change was measured, and the internal consistaccompany general cancer measures and are utilized to assess the unique problems faced by patients with differency for each scale was calculated. Coefficients of reliability and validity ranged from 0.86 to 0.89 for the ent diagnoses.
14,15
While many uses of QOL data have been described, 16 entire FACT-BMT and 0.54 to 0.63 for the BMTS. The BMTS was able to discriminate patients on the basis of there are three primary reasons why QOL measurement is important, especially in a BMT population. 17 First, when performance status rating and also demonstrated sensitivity to change over time. The FACT-BMT has good two treatments are compared in a clinical trial, QOL data may provide additional information upon which to base psychometric properties for use in assessing quality of life in bone marrow transplant patients. The addition treatment decisions. Since BMT regimens are relatively new compared to standard chemotherapeutic and radioof the bone marrow transplant subscale to the general FACT measure makes it an excellent choice for use in therapy regimens, and since BMT preparative regimens can produce significant side-effects, it is crucial to collect QOL BMT clinical trials. Keywords: quality of life; functional assessment; mardata on this patient population. This may be particularly important at a time when patient values and preferences row transplantation are being elicited and could be utilized in decision-making regarding complex treatments. [18] [19] [20] [21] Second, rehabilitation needs can be identified by QOL assessment, and rehabiliBone Marrow Transplantation (BMT) is associated with tation programs can be initiated and evaluated. This may many psychological and physical threats to quality of life, be especially important for BMT patients following the including lengthy hospitalization, isolation, frequent flucintensive treatment regimens where patients may need help tuations in medical status, invasive procedures, and the risk with physical, functional and emotional well-being. Third, of mortality from the procedure itself.
1,2 Patients are often psychosocial and QOL indices can be used as predictors of required to sacrifice current quality of life (QOL) for the response to future treatments. This is a newly developing area with preliminary findings indicating that psychological factors may have predictive value for survival following nology that affect the functioning and well-being of of 75 patients was assessed after transplantation, at hospital discharge. (One patient was unable to complete the entire patients. The Functional Assessment of Cancer TherapyBone Marrow Transplant Scale (FACT-BMT) was battery of instruments and was not included in the analysis, reducing the final total to 74). The post-bone marrow transdesigned to measure aspects of QOL in relation to bone marrow transplantation. It consists of the general Funcplant subset consisted of patients enrolled in a prospective longitudinal study on patient needs and quality of life foltional Assessment of Cancer Therapy (FACT-G) 13 and a Bone Marrow Transplantation Subscale (BMTS) which lowing bone marrow transplantation. The purpose of this study was to measure changes in QOL over a 1 year time assess specific BMT-related concerns. The FACT-G is an instrument widely used in clinical trials by a number of period. These were consecutively enrolled patients beginning in April 1994 to March 1995. In addition to the initial cooperative groups. 24 The primary goal of the FACT Measurement System is to assess the effects of cancer therassessment, the subsample was interviewed at hospital discharge, from 18 to 63 days later (mean days post-initial apy on patients in four major areas: physical well-being, social/family well-being, emotional well-being, and funcassessment = 28.9 (s.d. = 9.9) ). Additionally, descriptive statistics were reported for follow-up assessment at tional well-being. It also includes a subscale designed to measure the quality of the doctor-patient relationship. It approximately 100 days for 64 patients who continued in the post-transplant study. (Five of the 75 patients refused was developed with an emphasis on patient values and sensitivity to change over time. The FACT system includes to participate and six were deceased leaving a sample of 64 at 100 days). There were 60 patients for whom complete site-specific and symptom-specific subscales as well as this bone marrow transplant subscale. 25 The purpose of this data were available and analyzed at three time points: baseline, hospital discharge, and 100 days. Demographics for paper is to describe the development and psychometrics of the FACT-BMT.
these 60 patients were: mean age = 44.3 years (s.d. = 9.0); females = 37 (62%); Caucasian = 57 (95%); autologous BMT = 53 (88%), allogeneic BMT = 7 (12%). Information on demographics and clinical characteristics of all patients Materials and methods is provided in Table 1 . When patients were compared, only one patient characteristic differed significantly (lower perThe development of the FACT instrument and various sitespecific subscales have been described elsewhere. 13, 25, 26 centage of CML and Hodgkin's disease) from baseline to 100 days post-BMT. There were no other significant differThe development of the BMTS proceeded in the following manner. Patients who had received a BMT and experts in ences in the demographic variables and clinical characteristics recorded between this subset of patients at hospital the field of BMT were interviewed to generate potential scale items. Experts were defined as physicians or oncology discharge and at 100 days post-BMT. nurses with a minimum of 3 years experience treating at least 100 BMT patients. Fifteen patients and seven experts Procedure (five doctors and two nurses) were interviewed, producing a pool of 37 candidate questions. Twelve items were selecAll patients were scheduled for high-dose chemotherapy with BMT at the Comprehensive Cancer Center of Wake ted from this list. These were believed by the study team to be representative of the issues noted in the longer 37-Forest University, Bowman Gray School of Medicine/ North Carolina Baptist Hospital Medical Center. At baseitem list and to be non-redundant with the FACT-G item content. Thus, the subscale was designed to complement line, all patients were interviewed in their hospital room within 2 days of admission and prior to the onset of sidethe generic FACT-G instrument. We were attempting to capture an array of problems related to BMT and had no effects of the conditioning regimen. More than 95% of patients were interviewed on the day of admission prior to a priori expectation that the BMT subscale would measure a single dimension of QOL.
the initiation of their preparative regimen. An interview was conducted by a licensed, doctoral-level psychologist as part The FACT-G is scored by summing the five subscales yielding a composite quality of life score for each individof the psychosocial assessment at hospital admission. The four self-report instruments were explained by the psycholual. (Higher scores indicate better QOL.) The 12 items included in the BMTS were constructed to be compatible ogist who left them for the patient to complete. They were retrieved the following day. Patients were asked to fill in with the FACT-G. The item format is the same as the FACT-G and consists of a Likert-type scale ranging from any missing data at that point. The clinical interview consisted of questions about coping skills, a mental health his-0-4 (0 = not at all; 1 = a little bit; 2 = somewhat, 3 = quite a bit; and 4 = very much). Scoring procedures for the tory, difficulty of previous cancer therapies and available social support. The Eastern Cooperative Oncology Group BMTS are similar to those used for the FACT-G and consist of summing the items with reversed scoring for several (ECOG) performance status rating (PSR) 27 along with its descriptors was shown to patients who were asked to rate items which produces individual subscale scores and an overall score. 13 (See appendix 1 for the complete FACTthemselves (0 = I have normal activity; 1 = I have some symptoms, but I can walk and do not spend any extra time BMT and scoring guide.) in bed; 2 = I need some time in bed, but it is less than 50% of normal daytime; 3 = I need to be in bed greater than Patients 50% of normal daytime; 4 = I am unable to get out of bed).
Patients were then instructed to complete the FACT-BMT A total of 182 patients completed the FACT-BMT at hospital admission. For sensitivity to change analysis, a subset and three additional instruments which provided data rel- Allogeneic  37  20  11  15  7  11  Autologous  145  80  63  85  57  89 evant to construct validity. The brief Profile of Mood Statistical analysis States-Total Mood Disturbance Scale, (POMS-TMDS) is a 17-item measure of general distress measured over the past Descriptive statistics and composite scores were calculated for the FACT-BMT. Internal consistency (Cronbach's week. 28 The Center for Epidemiologic Studies-Depression (CES-D) screener scale consists of eight items and measAlpha) was calculated at baseline for 182 subjects and for a subsample of 74 and 64 patients at follow-up. The statistiures depressive symptoms over the past week. 29 The Medical Outcomes Study-Social Support (MOS-SS) survey is a cal procedure used (SAS CORR) allows for iterative reduction of items in order to maximize internal consist-20-item instrument that measures the patient's perceived social support. 30 The assessment procedure was explained ency. Sensitivity to change in performance status rating (PSR) was measured with the Wilcoxon rank sum test. A to all patients and any questions were answered. In the study of post-transplant functioning, 71 patients completed change of approximately 10% of the raw score was detectable in each subscale with alpha of 0.05, power of 0.80 the instruments 1 to 2 days prior to expected hospital discharge and three patients were interviewed by phone at with a sample of 60 patients across three time points. A series of repeated measures analyses of variance (ANOVA) home after they had been discharged. All remaining patients were interviewed by telephone again at approxiwas conducted on the FACT-BMT subscales and the individual BMTS items to assess their change over time in mately 100 days after transplantation. response to BMT. Repeated measures ANOVAs were the 10-item BMTS are reported in Table 3 . In order to determine if there were two or more factors inbedded in selected over a multivariate approach because the primary purpose was to examine the differential sensitivity of each the BMTS we conducted a factor analysis of the data. This did not yield discrete factors and did not improve alpha. subscale and item, rather than demonstrating the overall sensitivity of the total score.
Type of transplant
A sample of 74 patients was used to evaluate sensitivity to change in performance status relative to clinically meaningful change scores for FACT-G subscales and the BMTS (see Table 4 ). The Wilcoxon rank sum test was used to Results measure sensitivity to change in performance status rating (PSR). Patients were placed in one of two categories based The means, standard deviations, and Cronbach's Alpha (internal consistency) for the FACT-G subscales, total score on their PSR: (1) Decreased PSR (n = 50); or (2) no change/improved PSR (n = 23) based on the initial PSR and 12-item BMT subscale are presented in Table 2 . A 10-item BMTS and the Trial Outcome Index (TOI) are also prior to BMT. Mean change scores were calculated for each of the FACT subscales, the FACT-G total score, the FACTincluded in Table 2 . The TOI combines the Physical WellBeing subscale, the Functional Well-Being subscale, and BMT total score, and the Trial Outcome Index (TOI). Statistically significant results were recorded for the FACT-G the 10-item BMTS to form a precise and optimally sensitive measure of treatment effects. Baseline means are similar to (P Ͻ 0.0001) and the following subscales: Physical WellBeing (PWB, P Ͻ 0.0001); Social Well-Being (SWB, P those reported in the original FACT-G paper, 13 with the exception of Social Well-Being, which appears somewhat = 0.0151); Relationship With Doctor (RWD, P = 0.0431); Functional Well-Being (FWB, P = 0.0006); the 10-item higher in the BMT sample.
Cronbach's Alpha on the 12-item BMTS ranged from BMTS (P = 0.0183); and the TOI (P Ͻ 0.0001). The TOI is an aggregate score of the PWB, FWB and the 10-item 0.52 to 0.60. In subsequent analysis we set aside two items: 'I regret having the transplant' and 'I have concerns about BMTS. The utility of this type of index has been reported in lung cancer patients. 25 The 24-item TOI in this patient my ability to have children', due to poor statistical fit. The resulting 10-item scale produced an alpha coefficient that population was reliable (alpha ranged from 0.79 to 0.88 over three administrations) and highly sensitive to change ranged from 0.54 to 0.63. The alpha coefficient for the total FACT-BMT (FACT-G plus the 10-item BMTS) ranged in PSR (P Ͻ 0.0001). Detailed analysis of the FACT-BMT subscale scores and from 0.85 to 0.92 (see Table 2 ). Inter-item correlations for Table 2 FACT-BMT descriptive statistics prior to BMT and at follow-up 0.02 Confidence in nurses *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001. n = 182, alpha for entire 10-item scale = 0.63.
Table 4
Sensitivity of FACT BMT to change in performance status rating (PSR) (n = 73) Mean change scores were calculated by subtracting mean scores at baseline from mean scores at hospital discharge.
their relationship to patient rated performance status are charge, then return toward baseline at 100 days. P-values for pairwise (unadjusted) comparisons are also reported in reported in Table 5 . In almost all cases, where differences between the PSR groups occurred, these differences were Table 6 , assessing the change between each of the three time points. in the expected direction reflecting poorer QOL (lower scores) in patients with worse (higher) performance rating.
Mean scores for individual items on the BMTS are reported in Table 7 . Six items demonstrate statistically sigRepeated measures ANOVAs on the 60 patients who were assessed at all three time points for the FACT-BMT nificant change over the three time periods. Patients were less concerned about keeping their job after transplantation. and subscales are reported in Table 6 . In the test across time, statistically significant differences were observed for Patients reported getting tired more easily at 100 days than at discharge or baseline. On three items (good appetite, like the FACT-BMT (worsens, then improves, P = 0.008) and for the following subscales: Physical Well-Being (worsens, body appearance, and confidence in nurses) patients reported more concern at discharge than at 100 days. then improves, P = 0.007), Emotional Well-Being (improves, P = 0.0003), Functional Well-Being (worsens, Patients were less interested in sex at discharge than at 100 days. Patients were more worried that the transplant would then improves, P = 0.0002), the TOI (worsens, then improves, P = 0.0001) and the BMTS (worsens, then not work at 100 days than at discharge. Any regret about having the transplant was low and remained so over the improves, P = 0.0001). The FACT-G approaches significance, with a P-value = 0.059 as the scores drop at disthree time points. Ratings were made by patients who were asked to place themselves in one of the following categories: 0 = I have normal activity; 1 = I have some symptoms, but I can walk and I do not spend any extra time in bed; 2 = I need some time in bed, but it is less than 50% of normal daytime; 3 = I need to be in bed greater than 50% of normal daytime; 4 = I am unable to get out of bed. b Analysis of Variance measures the significance of difference in subscale scores over Performance Status Ratings of 0, 1, 2, 3. c Scheffe comparisons: Ͼ Symbol separates groups that report significantly higher scores from those with lower scores. d Since there was only one patient who reported a PSR score of zero, this patient's scores on the FACT were included in the group that reported a PSR of one. e Since there was only one patient who reported a PSR score of four, this patient's scores on the FACT were included in the group who reported a PSR of three.
Table 6
FACT-G and FACT-BMT repeated measures ANOVA (n = 60) The question of construct validity (Does the FACTcorrelation coefficients in Table 8 Means are given as reported by patients, prior to scoring reversals. Items 35-38, 42, 44, and 46 are reversed prior to scoring into the BMTS, so that high scores on the BMTS reflect relatively better QOL.
Table 8
Construct (concurrent) validity coefficients (n = 182) between the Emotional Well-Being subscale and the Brief patients on the FACT. Patients who received autologous BMT did not differ significantly from allogeneic patients POMS (−0.69) and the CES-D (−0.52) are also high. Finally, the correlation between Social Well-Being and the on the FACT or any of its subscales. Furthermore, there were no differences between the patients with graft-versusMedical Outcome-Social Support Survey is 0.50. All of these findings provide evidence for construct (convergent) host disease (GVHD) (10/74 at discharge and 7/64 at 100 days) and those without GVHD on the FACT-BMT and validity. That is, these FACT subscales measure constructs similar to those measured in performance status rating, the subscales. Brief POMS, the CES-D and the MOS-SS. Evidence of divergent validity, ie the lack of relationship between different constructs, can be seen, for example, in the low corDiscussion relation between the Social Support Survey and the Physical Well-Being subscale of the FACT (0.13). As expected,
We have described the development of a Bone Marrow Transplant Subscale (BMTS) to accompany the core given the item content, the BMTS correlates highly with the FACT-G, the Physical (0.60) and Functional (0.60) FACT-G scale. Items were generated to take into account the treatment experience of patients undergoing high-dose Well-Being subscales and less so with the Relationship with Doctor subscale (0.24) and MOS social support surintensive chemotherapy and radiotherapy regimens with bone marrow transplant rescue. The BMTS was designed vey (0.29).
We compared autologous and allogeneic transplant to complement version 3 of the FACT-G. 31 Two items were set aside from the original 12-item BMTS ('I have concerns points on the 10-item BMTS which can therefore be considered clinically meaningful. Assuming that this degree of about my ability to have children' and 'I regret having the bone marrow transplant') since they were not highly correchange in the subscale reflects a clinically meaningful experience for the patient is consistent with other lated with the remaining 10 items. Nevertheless, these items may prove to be relevant. We recommend that these two researchers. 25, [33] [34] [35] Four subscales on the FACT-BMT as well as the TOI items continue to be administered, that they not be included in the FACT-BMT scoring, and that they be viewed as record statistically significant changes in the expected direction at the three time points (Table 6 ). The Physical single items.
The alpha coefficient (internal consistency) was included Well-Being, Functional Well-Being, and BMT subscales, and the TOI decrease at discharge, reflecting poorer QOL; in our analysis because of its role as a standard in psychometrics. However, it should be stressed that the alpha coefthey return to near baseline rates at 100 days, reflecting patient improvement during this time period. This might be ficient is, in fact, only a measure of homogeneity, or consistency of response. In classical test theory, variable error expected, since Physical Well-Being and Functional WellBeing are adversely affected in the short run by bone mar-(reliability) is defined in terms of 'consistency of performance' on items on a test. 32 However, 'such a definition is row transplantation. However, at 100 days improved QOL is reflected in increased scores on this subscale. The not acceptable where the test items lack complete homogeneity' (p 70). In other words, lack of consistency of Emotional Well-Being subscale score increases from baseline to discharge and then remains nearly the same from response on a heterogeneous scale is not necessarily a reflection of error, but merely a function of the scale's discharge to 100 days, reflecting improvement from baseline to 100 days. The Relationship with the Doctor subscale complex nature.
Items on the BMTS are heterogeneous, since it was score increases from baseline to discharge and decreases from discharge to 100 days, perhaps reflecting the reduced developed as a miscellaneous category, consisting of QOL items not included in the general scale. Its items measure contact with the physician following inpatient care. Two individual items, 'The effects of treatment are worse factors that can change (in either direction) with a BMT, but are not necessarily from a single domain (physical, than I imagined' and 'I get tired easily' change in the expected direction from baseline to discharge: patients tire emotional, functional, etc). Because of this complexity, the alpha coefficients for the BMTS will be lower than those more easily and experience the effects of treatment as more difficult than they imagined from discharge to 100 days, reported for homogeneous scales. We recommend that investigators check alpha in their sample when using the perhaps reflecting the tenacity of side effects that persist over long periods of time following bone marrow transplan-FACT-BMT. If it is not acceptable, use multiple individual comparison of the items. However, it is likely that the tation. In items 39 (good appetite), 40 (like body appearance) and 43 (interest in sex), mean scores decrease BMTS can be used and added to the FACT-G for acceptable alpha. We are currently working on applying analyses from baseline to hospital discharge and increase from discharge to 100 days. As would be expected, QOL as measwhich may be more appropriate for this type of scale.
Sensitivity to change is an important characteristic of any ured by these items is impaired but at 100 days returns to near baseline levels. In item 37 (worry that the transplant instrument used in clinical trials. The 74 patients who form the subgroup where change was measured were assessed at won't work), mean scores decline from baseline to discharge, reflecting less worry about the transplant working. hospital discharge following the bone marrow transplantation process. The majority of these patients (50/74) However, at 100 days, mean scores return to near baseline levels, which are still relatively low, ie (1.0 = a little bit). reported a decrease in performance status rating. The mean BMTS (10 item) score changed −3.3 points (s.d. = 4.4) in While item 46, 'I regret having the bone marrow transplant', has been set aside in the analysis due to poor statistithe 50 patients whose PSR decreased, and changed −0.5 (s.d. = 5.3) in the 23 patients whose PSR remained the same cal fit, it is reported here since mean scores range from 0.01 to 0.2 after transplantation indicating that few people in this or improved. The BMTS provides a more detailed analysis when compared with the ECOG PSR. Thus, it is not sursample reported any regret about having the BMT. The population used in this report consisted of 20% (n = prising that the BMTS decreased slightly across time in the patients where PSR stayed the same or improved slightly. 37) allogeneic and 80% (n = 145) autologous bone marrow transplant patients. While this population mix does not This points out the sensitivity of the BMTS. The individual items that make up a scale could vary slightly with no directly affect the psychometric properties of the BMTS, allogeneic patients may demonstrate more serious and difattendant change in performance status rating. For example, it is conceivable that mean scores on 'I like the appearance ferent side-effects at follow-up administrations of the scale when compared to autologous patients. 36 Presumably, such of my body' could drop while not affecting performance status rating. This also could be true of items 35 (concern differences would be readily detectable by the FACT-BMT since it has demonstrated sensitivity to change in this samabout job), 36 (feel distant from people), 37 (worry transplant won't work), 43 (interested in sex), and 45
ple. In this sample, there were no statistically significant differences in QOL when autologous were compared with (confidence in nurses).
A change of one point or more on the ECOG PSR is allogeneic transplant patients at discharge and 100 days. However, it is likely that any differences between alloclinically meaningful, particularly from the patients' perspective where a change of this magnitude is associated geneic and autologous BMT patients would not be detectable with so few allogeneic patients. Further development with increased symptoms. The ECOG PSR change of one point is associated with a mean change of two to three of the scale with a variety of patients who differ according tation, etc, will provide information on QOL changes that affect patients differentially. The Trial Outcome Index (TOI) has been developed as a highly sensitive measure of patient symptoms and can be References utilized in clinical trials. It has also been described for lung cancer patients. 25 In this bone marrow transplant sample, single indicator which combines these three related areas, (eg worry that the transplant won't work) while others 
